Stockholm, 2014-04-23 08:30 CEST (GLOBE NEWSWIRE) --
PledPharma has received approval from the DSMB (Drug Safety Monitoring Board, an independent panel of experts) to also include patients being treated with a combination of FOLFOX and Avastin (bevacizumab) in the randomized part of the Phase IIb study PLIANT.
The approval comes after the DSMB has analyzed the data from the first three patients enrolled in the study with this combination. Bevacizumab is commonly used in cancer treatment and the combination FOLFOX / bevacizumab can now be used at all centers in the PLIANT study.
For further information, please contact:
Jacques Näsström, CEO
+46 737 13 09 79
Jacques.nasstrom@pledpharma.se
Michaela Gertz, CFO
+46 709 26 17 75
Michaela.gertz@pledpharma.se
About PledPharma
PledPharma is a Swedish pharmaceutical company that develops new therapies for the treatment of life threatening diseases. The initial objective is to develop a drug, PledOx®, which reduces severe side-effects associated with chemotherapy. The current market for supportive cancer care is some USD 10 billion. PledPharma also evaluates an existing medicines possibility to reduce the damage that occurs on the heart muscle when patients suffer from acute myocardial infarction. In addition to these projects, the company is also evaluating opportunities of using our technology platform in additional areas where there is a significant unmet medical need. PledPharma has the potential to offer patients valuable and unique treatments for serious life-threatening diseases where there is an opportunity fast registration in the US through "breakthrough therapy" designation. This means that the company has the potential to offer shareholders a good return on their investment. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
